The Patients’ Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter Pylori Eradication Regimens

Abbasinazari, Mohammad; Sahraee, Zahra; Mirahmadi, Maryam

doi:10.7860/jcdr/2013/4673.2799

Cited by 12 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VAP remains a serious complication amongst critical care patients in any healthcare setting and its incidence has been found to be highly variable not only amongst hospitals, but also in different ICUs in the same hospital. The infection rates seen in the present study were comparable to the figures of 35.1 and 37 per cent in two different studies from India 17 18 . The VAP rate per 1000 ventilator days is a commonly used parameter worldwide, and although its rate was quite low in the USA (4.4) 4 , in various other countries, it was found to be high in the range of 13-51 per 1000 ventilator days 5 .…”

Section: Discussionsupporting

confidence: 89%

“…In our study, the Gram-negative bacilli were the principal isolates, and Pseudomonas spp., non-fermenters and Klebsiella spp. were the most common pathogens with almost similar proportion of frequency, and these findings were corroborated by other Indian studies 17 25 .…”

Section: Discussionsupporting

confidence: 87%

“…in our study and amongst the non-fermenters, 33.1 per cent of the strains became IPM resistant by 2013. In one Indian study, the figures were 40 and 37.5 per cent for P. aeruginosa and Acinetobacter spp., respectively 17 . In Europe, the non-susceptibility rates for P. aeruginosa have been reported to increase to about 20 per cent for carbapenems, 25 per cent for aminoglycosides and about 8 per cent for PTZ 30 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India

Chaudhury

Rani

Kalawat

et al. 2016

Indian Journal of Medical Research

View full text Add to dashboard Cite

Background & objectives:Ventilator-associated pneumonia (VAP) is an important hospital-acquired infection with substantial mortality. Only a few studies are available from India addressing the microbiological aspects of VAP, which have been done with small study populations. This study was carried out in the intensive care units (ICUs) of a tertiary care hospital to assess the profile of pathogens and to determine the pattern of antimicrobial resistance.Methods:This was a retrospective study of clinically suspected cases of VAP. Over a three year period, a total of 247 cases in 2011, 297 in 2012 and 303 in 2013 admitted in ICUs on mechanical ventilation with clinical evidence of VAP were included in our study. The endotracheal aspirate samples from these suspected cases were subjected to quantitative culture technique, and colony count of ≥105 colony forming units/ml was considered significant. Antimicrobial susceptibility test for the isolates was done.Results:VAP rates of 44.1, 43.8 and 26.3 were seen in 2011, 2012 and 2013, respectively. In all the three years, non-fermentative Gram-negative bacilli were the predominant organisms, followed by Pseudomonas spp. and Klebsiella spp. Staphylococcus aureus exhibited a downwards trend in prevalence from 50.0 per cent in 2011 to 34.9 per cent in 2013. An increase in vancomycin-resistant enterococci was seen from 4.3 per cent in 2012 to 8.3 per cent in 2013, while methicillin resistance amongst the S. aureus crossed the 50 per cent mark in 2013. An increasing trend in resistance was shown by Pseudomonas spp. for piperacillin-tazobactam (PTZ), amikacin and imipenem (IPM). For the non-fermenters, resistance frequency remained very high except for IPM (33.1%) and polymyxin-B (2.4%).Interpretation & conclusions:Our findings show VAP as an important problem in the ICU setting. The incidence of multidrug-resistant pathogens was on the rise. The resistance pattern of these pathogens can help an institution to formulate effective antimicrobial policy. To have a comprehensive pan-India picture, multicentric studies are needed.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India

Chaudhury

Rani

Kalawat

et al. 2016

Indian Journal of Medical Research

View full text Add to dashboard Cite

show abstract

“…However, most studies performed in China revealed that the compliance during H pylori eradication is unpleasant in clinical practice . A prospective study conducted by Abbasinazari et al reported that while regimen type was not relative to patients’ adherence, the frequency of dosing and numbers of medications affected the adherence to treatment. In the present study, the SMRE induced an increased number of patients taking more than 90% of prescribed drugs (84.8% vs 72.8%, P = 0.011), while the number of patients taking <60% of pills were similar in two groups (3.4% vs 2.1%, P = 0.780).…”

Section: Discussionmentioning

confidence: 99%

Twice daily short‐message‐based re‐education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study

Wang

Yang

et al. 2019

Helicobacter

View full text Add to dashboard Cite

Background To investigate the effects of twice daily short‐message‐based re‐education (SMRE) before taking medicine for Helicobacter pylori (H pylori) eradication. Materials and Methods Treatment‐naive patients with H pylori infection were prescribed 14‐day quadruple regimen consisting of lansoprazole 30 mg, colloidal bismuth pectin 200 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily. Patients were randomly allocated to SMRE group or control group. Patients in control group received oral and written instructions at outpatient clinic. In contrast, patients in the SMRE group received extra short messages including dosage and time of administration twice daily. Successful H pylori eradication was assessed using the 13C‐urea breath test 6 weeks after treatment. The compliance, adverse events, and patient satisfaction were also analyzed. Results A total of 310 patients were enrolled in the intention‐to‐treat (ITT) and 283 in the per‐protocol (PP) analysis. For young patients, the eradication rates were significantly higher in SMRE group than those in control group in PP analysis (88.6% vs 71.2%, P = 0.036), while for patients of all age groups, the eradication rate improvements were not statistically significant. The eradication rates in SMRE group and control group were 74.2% and 67.7% (P = 0.211) in ITT analysis and 82.1% and 73.4% (P = 0.078) in PP analysis, respectively. The compliance in SMRE group was significantly better than that in control group (84.8% vs 72.8%, P = 0.011). Conclusions Twice daily SMRE could improve the eradication rate in young population, as well as the compliance with treatment during H pylori eradication.

show abstract

“…For HP infection, clinical triple therapy is commonly used. [ 10 ] However, because of the poor compliance of patients, [ 11 ] emerging resistant HP strains [ 9 , 12 – 14 ] and adverse drug reactions, [ 15 – 17 ] the clinical eradication rate of HP has decreased to an unacceptable low level, [ 18 ] which lead to recurrence frequently. [ 19 , 20 ] The long course of the disease needs to take medicine for a long time, causing great psychological pressure [ 21 , 22 ] to the patient and increasing substantial healthcare costs, which cause significant reductions in patients’ quality of life.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of Zuojin Pill for chronic gastritis

Shi

Liu

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Chronic gastritis (CG), as the highest incidence of gastrointestinal diseases, has been gradually increasing around globally. With the obvious disadvantages of standard treatment, more and more people ask the traditional Chinese medicine for help in the treatment of CG. As a traditional Chinese medicine compound, Zuojin Pill (ZJP) has a long history of clinical application in the treatment of digestive system diseases. Whereas, neither systematic nor meta-analysis of randomized controlled trials explain the efficacy and safety of ZJP in treating CG. Thus, we provide a protocol to evaluate the efficacy and safety of ZJP for CG. Methods: From the beginning to December 2019, the following electronic databases will be searched for studies in English or Chinese: the Cochrane Library, Embase, PubMed, Web of Science, the Chinese National Knowledge Infrastructure, the Chinese Biomedical Literature Database, the Chinese Scientific Journal Database, and the Wanfang Database. Clinical efficiency, helicobacter pylori infection clearance rate, quality of life and symptom scores will be measured as primary outcomes. Meta-analysis will be performed using the Stata 15. Outcomes: This study will provide the current evidence of CG treated with ZJP from the several aspects including clinical efficiency, helicobacter pylori infection clearance rate, quality of life, symptom scores, the 1-year recurrent rate, efficacy under endoscopy and number of reported adverse events associated with the use of ZJP. Conclusion: The outcomes of this review will be served as a proof to evaluate if ZJP is effective in the treatment of CG. PROSPERO registration number: PROSPERO CRD42020155036.

show abstract

The Patients’ Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter Pylori Eradication Regimens

Cited by 12 publications

References 12 publications

Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India

Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India

Twice daily short‐message‐based re‐education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study

Efficacy and safety of Zuojin Pill for chronic gastritis

Contact Info

Product

Resources

About